Axsome Therapeutics (AXSM) Equity Average (2022 - 2025)
Historic Equity Average for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $73.4 million.
- Axsome Therapeutics' Equity Average fell 2500.54% to $73.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year decrease of 2500.54%. This contributed to the annual value of $124.0 million for FY2024, which is 1748.26% down from last year.
- Axsome Therapeutics' Equity Average amounted to $73.4 million in Q3 2025, which was down 2500.54% from $63.1 million recorded in Q2 2025.
- Axsome Therapeutics' 5-year Equity Average high stood at $274.2 million for Q3 2023, and its period low was $14.9 million during Q2 2022.
- In the last 4 years, Axsome Therapeutics' Equity Average had a median value of $104.3 million in 2023 and averaged $121.5 million.
- As far as peak fluctuations go, Axsome Therapeutics' Equity Average soared by 120651.83% in 2023, and later crashed by 6744.45% in 2024.
- Quarter analysis of 4 years shows Axsome Therapeutics' Equity Average stood at $133.5 million in 2022, then soared by 72.52% to $230.2 million in 2023, then tumbled by 67.44% to $75.0 million in 2024, then decreased by 2.08% to $73.4 million in 2025.
- Its Equity Average was $73.4 million in Q3 2025, compared to $63.1 million in Q2 2025 and $55.1 million in Q1 2025.